Raymond James Keeps a Hold Rating on Aerie Pharma (AERI)

In a report released today, Elliot Wilbur from Raymond James maintained a Hold rating on Aerie Pharma (AERI). The company’s shares closed last Monday at $11.57, close to its 52-week low of $10.22.

According to TipRanks.com, Wilbur is ranked 0 out of 5 stars with an average return of -3.4% and a 41.2% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Sol-Gel Technologies, and ANI Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerie Pharma with a $27.50 average price target.

See today’s analyst top recommended stocks >>

Based on Aerie Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $20.34 million and GAAP net loss of $49.13 million. In comparison, last year the company earned revenue of $15.84 million and had a GAAP net loss of $47.16 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.